TY - JOUR
T1 - Optimising experimental research in respiratory diseases
T2 - an ERS statement
AU - Bonniaud, Philippe
AU - Fabre, Aurelie
AU - Frossard, Nelly
AU - Guignabert, Christophe
AU - Inman, Mark
AU - Kuebler, Wolfgang M.
AU - Maes, Tania
AU - Shi, Wei
AU - Stampfli, Martin
AU - Uhlig, Stefan
AU - White, Eric
AU - Witzenrath, Martin
AU - Bellaye, Pierre-Simon
AU - Crestani, Bruno
AU - Eickelberg, Oliver
AU - Fehrenbach, Heinz
AU - Guenther, Andreas
AU - Jenkins, Gisli
AU - Joos, Guy
AU - Magnan, Antoine
AU - Maitre, Bernard
AU - Maus, Ulrich A.
AU - Reinhold, Petra
AU - Vernooy, Juanita H. J.
AU - Richeldi, Luca
AU - Kolb, Martin
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Experimental models are critical for the understanding of lung health and disease and are indispensable for drug development. However, the pathogenetic and clinical relevance of the models is often unclear. Further, the use of animals in biomedical research is controversial from an ethical perspective. The objective of this task force was to issue a statement with research recommendations about lung disease models by facilitating in-depth discussions between respiratory scientists, and to provide an overview of the literature on the available models. Focus was put on their specific benefits and limitations. This will result in more efficient use of resources and greater reduction in the numbers of animals employed, thereby enhancing the ethical standards and translational capacity of experimental research. The task force statement addresses general issues of experimental research (ethics, species, sex, age, ex vivo and in vitro models, gene editing). The statement also includes research recommendations on modelling asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, lung infections, acute lung injury and pulmonary hypertension. The task force stressed the importance of using multiple models to strengthen validity of results, the need to increase the availability of human tissues and the importance of standard operating procedures and data quality.
AB - Experimental models are critical for the understanding of lung health and disease and are indispensable for drug development. However, the pathogenetic and clinical relevance of the models is often unclear. Further, the use of animals in biomedical research is controversial from an ethical perspective. The objective of this task force was to issue a statement with research recommendations about lung disease models by facilitating in-depth discussions between respiratory scientists, and to provide an overview of the literature on the available models. Focus was put on their specific benefits and limitations. This will result in more efficient use of resources and greater reduction in the numbers of animals employed, thereby enhancing the ethical standards and translational capacity of experimental research. The task force statement addresses general issues of experimental research (ethics, species, sex, age, ex vivo and in vitro models, gene editing). The statement also includes research recommendations on modelling asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, lung infections, acute lung injury and pulmonary hypertension. The task force stressed the importance of using multiple models to strengthen validity of results, the need to increase the availability of human tissues and the importance of standard operating procedures and data quality.
KW - IDIOPATHIC PULMONARY-FIBROSIS
KW - ACUTE LUNG INJURY
KW - COMMUNITY-ACQUIRED PNEUMONIA
KW - CIGARETTE-SMOKE EXPOSURE
KW - INBRED MOUSE STRAINS
KW - ALLERGIC AIRWAY INFLAMMATION
KW - HIGHLAND WHITE TERRIERS
KW - ANIMAL-MODELS
KW - DISTRESS-SYNDROME
KW - ARTERIAL-HYPERTENSION
U2 - 10.1183/13993003.02133-2017
DO - 10.1183/13993003.02133-2017
M3 - Article
C2 - 29773606
SN - 0903-1936
VL - 51
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 5
M1 - 1702133
ER -